MedTrace Logo

Risk and Resilience in Pulmonary Arterial Hypertension and Genetically Susceptible Individuals

NCT05584722 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 150

Last updated 2026-03-10

No results posted yet for this study

Summary

Pulmonary arterial hypertension (PAH) is a severe disease with a delayed diagnosis and markedly elevated mortality. High-risk populations, such as those with known genetic defects, provide a unique opportunity to determine the features of susceptibility and resilience to PAH. This proposal will fundamentally overturn the prevailing understanding of PAH by creating molecularly-driven signatures of susceptibility and resilience, provide novel insight into disease severity, and potentially identify new therapeutic targets.

Funding Source - FDA OOPD

Conditions

  • Idiopathic Pulmonary Arterial Hypertension
  • Heritable Pulmonary Arterial Hypertension
  • Unaffected Mutation Carriers: Healthy Participants With a Known BMPR2 Gene Mutation and Normal Pulmonary Pressure and RV Function on Echo
  • Healthy Individuals With no Cardiopulmonary Disease

Sponsors & Collaborators

  • Vanderbilt University Medical Center

    lead OTHER

Principal Investigators

  • Evan Brittain, MD · Vanderbilt Medical Center

  • Anna Hemnes, MD · Vanderbilt Medical Center

  • Eric Austin, MD · Vanderbilt Medical Center

Eligibility

Min Age
15 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-11-01
Primary Completion
2026-08-31
Completion
2026-08-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05584722 on ClinicalTrials.gov